Literature DB >> 22777335

Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer.

Vincent Vinh-Hung1, Hendrik Everaert, Jan Lamote, Mia Voordeckers, Hilde van Parijs, Marian Vanhoeij, Guy Verfaillie, Christel Fontaine, Hansjoerg Vees, Osman Ratib, Georges Vlastos, Mark De Ridder.   

Abstract

PURPOSE: To explore the preoperative utility of FDG PET for the diagnosis and prognosis in a retrospective breast cancer case series.
METHODS: In this retrospective study, 104 patients who had undergone a preoperative FDG PET scan for primary breast cancer at the UZ Brussel during the period 2002-2008 were identified. Selection criteria were: histological confirmation, FDG PET performed prior to therapy, and breast surgery integrated into the primary therapy plan. Patterns of increased metabolism were recorded according to the involved locations: breast, ipsilateral axillary region, internal mammary chain, or distant organs. The end-point for the survival analysis using Cox proportional hazards was disease-free survival. The contribution of prognostic factors was evaluated using the Akaike information criterion and the Nagelkerke index.
RESULTS: PET positivity was associated with age, gender, tumour location, tumour size >2 cm, lymphovascular invasion, oestrogen and progesterone receptor status. Among 63 patients with a negative axillary PET status, 56 (88.9 %) had three or fewer involved nodes, whereas among 41 patients with a positive axillary PET status, 25 (61.0 %) had more than three positive nodes (P < 0.0001). In the survival analysis of preoperative characteristics, PET axillary node positivity was the foremost statistically significant factor associated with decreased disease-free survival (hazard ratio 2.81, 95% CI 1.17-6.74).
CONCLUSION: Preoperative PET axillary node positivity identified patients with a higher burden of nodal involvement, which might be important for treatment decisions in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22777335     DOI: 10.1007/s00259-012-2181-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

1.  Multiple imputation of discrete and continuous data by fully conditional specification.

Authors:  Stef van Buuren
Journal:  Stat Methods Med Res       Date:  2007-06       Impact factor: 3.021

Review 2.  The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature.

Authors:  Rebecca Peare; R T Staff; S D Heys
Journal:  Breast Cancer Res Treat       Date:  2010-02-07       Impact factor: 4.872

3.  Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.

Authors:  A Avril; G Le Bouëdec; G Lorimier; J M Classe; C Tunon-de-Lara; S Giard; G MacGrogan; M Debled; S Mathoulin-Pélissier; L Mauriac
Journal:  Eur J Surg Oncol       Date:  2011-06-12       Impact factor: 4.424

4.  18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.

Authors:  Joseph R Osborne; Elisa Port; Mithat Gonen; Ashley Doane; Henry Yeung; William Gerald; Josh B Cook; Steven Larson
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

5.  Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.

Authors:  Patrick G Morris; Gary A Ulaner; Anne Eaton; Maurizio Fazio; Komal Jhaveri; Sujata Patil; Laura Evangelista; Joseph Y Park; Cristian Serna-Tamayo; Jane Howard; Steven Larson; Clifford A Hudis; Heather L McArthur; Maxine S Jochelson
Journal:  Cancer       Date:  2012-04-19       Impact factor: 6.860

6.  Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.

Authors:  Pierre Heudel; Sebastien Cimarelli; Anthony Montella; Catherine Bouteille; Thomas Mognetti
Journal:  Int J Clin Oncol       Date:  2010-09-01       Impact factor: 3.402

7.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal:  J Nucl Med       Date:  2002-04       Impact factor: 10.057

Review 8.  NCCN task force: clinical utility of PET in a variety of tumor types.

Authors:  Donald A Podoloff; Douglas W Ball; Edgar Ben-Josef; Al B Benson; Steven J Cohen; R Edward Coleman; Dominique Delbeke; Maria Ho; David H Ilson; Gregory P Kalemkerian; Richard J Lee; Jay S Loeffler; Homer A Macapinlac; Robert J Morgan; Barry Alan Siegel; Seema Singhal; Douglas S Tyler; Richard J Wong
Journal:  J Natl Compr Canc Netw       Date:  2009-06       Impact factor: 11.908

9.  The use of molecular imaging to evaluate radiation fields in the adjuvant setting of breast cancer: a feasibility study.

Authors:  Samuel Bral; Vincent Vinh-Hung; Hendrik Everaert; Peter De Coninck; Guy Storme
Journal:  Strahlenther Onkol       Date:  2008-02       Impact factor: 3.621

10.  Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.

Authors:  Tomoo Inoue; Kenji Yutani; Tetsuya Taguchi; Yasuhiro Tamaki; Eiichi Shiba; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-24       Impact factor: 4.553

View more
  10 in total

1.  Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?

Authors:  Dimitri Bellevre; Cécile Blanc Fournier; Odile Switsers; Audrey Emmanuelle Dugué; Christelle Levy; Djelila Allouache; Cédric Desmonts; Hubert Crouet; Jean-Marc Guilloit; Jean-Michel Grellard; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

2.  Pretreatment PET in breast cancer: is there a role?

Authors:  Sue Chua; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12       Impact factor: 9.236

3.  Preoperative FDG PET/CT in breast cancer patients: where are we going?

Authors:  Laura Gilardi; Concetta De Cicco; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11       Impact factor: 9.236

4.  Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.

Authors:  Diomidis Botsikas; Anastasia Kalovidouri; Minerva Becker; Michele Copercini; Dahila Amal Djema; Alexandre Bodmer; Sindy Monnier; Christoph D Becker; Xavier Montet; Benedicte M A Delattre; Osman Ratib; Valentina Garibotto; Claire Tabouret-Viaud
Journal:  Eur Radiol       Date:  2015-10-17       Impact factor: 5.315

5.  Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.

Authors:  Subrata K Ghosh; Masashi Uchida; Byunghee Yoo; Alana W Ross; Sandra J Gendler; Jianlin Gong; Anna Moore; Zdravka Medarova
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

6.  Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast.

Authors:  I Jo; Seok Kil Zeon; Sung Hoon Kim; Hae Won Kim; Sun Hee Kang; Sun Young Kwon; Su Jin Kim
Journal:  Nucl Med Mol Imaging       Date:  2014-10-02

7.  Preoperative [18]fluorodeoxyglucose-positron emission tomography/computed tomography in early stage breast cancer: Rates of distant metastases.

Authors:  Vincent Vinh-Hung; Hendrik Everaert; Karim Farid; Navid Djassemi; Jacqueline Baudin-Veronique; Stefanos Bougas; Yuriy Michailovich; Clarisse Joachim-Contaret; Elsa Cécilia-Joseph; Claire Verschraegen; Nam P Nguyen
Journal:  World J Radiol       Date:  2017-07-28

8.  Correlation of Maximum Standardized Uptake Values in 18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Scan with Immunohistochemistry and Other Prognostic Factors in Breast Cancer.

Authors:  Zakir Ali Abubakar; Naveen Kumar Reddy Akepati; Prathyusha Bikkina
Journal:  Indian J Nucl Med       Date:  2019 Jan-Mar

9.  Gini's mean difference and the long-term prognostic value of nodal quanta classes after pre-operative chemotherapy in advanced breast cancer.

Authors:  Vincent Vinh-Hung; Hilde Van Parijs; Olena Gorobets; Christel Fontaine; Nam P Nguyen; Bhumsuk Keam; Dung Minh Nguyen; Mark De Ridder
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

10.  Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis.

Authors:  Justine Perrin; Karim Farid; Hilde Van Parijs; Olena Gorobets; Vincent Vinh-Hung; Nam P Nguyen; Navid Djassemi; Mark De Ridder; Hendrik Everaert
Journal:  World J Clin Oncol       Date:  2022-04-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.